Evoke Pharma (NASDAQ:EVOK) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research report report published on Wednesday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Down 2.8 %

Evoke Pharma stock opened at $3.14 on Wednesday. Evoke Pharma has a 52-week low of $1.94 and a 52-week high of $12.32. The firm has a market cap of $4.69 million, a PE ratio of -0.29 and a beta of 0.16. The company’s 50 day moving average is $2.83 and its two-hundred day moving average is $4.10.

Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings data on Thursday, March 13th. The specialty pharmaceutical company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.24). Evoke Pharma had a negative return on equity of 308.49% and a negative net margin of 71.32%. The company had revenue of $3.31 million for the quarter, compared to analyst estimates of $3.08 million.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Evoke Pharma stock. Nantahala Capital Management LLC boosted its stake in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) by 163.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 148,194 shares of the specialty pharmaceutical company’s stock after acquiring an additional 91,945 shares during the quarter. Nantahala Capital Management LLC owned about 9.95% of Evoke Pharma worth $655,000 as of its most recent filing with the Securities and Exchange Commission.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.